Veracyte Announces Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Veracyte, Inc (VCYT) PT Raised to $34 at Needham & Company
July 31, 2019 8:25 AM EDTNeedham & Company analyst Stephen Unger raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $34.00 (from $33.00) while maintaining a Buy rating.
The analyst commented, "Last night, VCYT reported solid 2Q19 results, with total revenues rising 32.5% y/y to $30.1M - $1.1M above our... More
Veracyte (VCYT) Tops Q2 EPS by 5c, Revenues Beat; Raises FY19 Revenue Guidance
July 30, 2019 5:01 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.05), $0.05 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $30.1 million versus the consensus estimate of $28.84 million.
Our strong second quarter performance was fueled by the growth of our products in three clinical indications, biopharmaceutical services revenue from milestone achievements and operational and financial discipline, said Bonnie Anderson, chairman and chief executive officer of Veracyte. In addition, we... More
